Kiora Pharmaceuticals (KPRX) Research & Development (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Research & Development came in at $2.1 million in Q1 2026, down 16.12% YoY from $2.5 million in Q1 2025, and up 21.18% on a QoQ basis from $1.8 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Research & Development (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Research & Development data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Research & Development fell 16.12% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 36.69% YoY) and the FY2025 annual result came in at $7.1 million, down 9.95% from the prior year.
- Research & Development grew to $2.1 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.5 million in Q1 2025 to a low of $189904.0 in Q1 2024.
- A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development plunged 60.61% — and 2025, when it soared 1233.25%.
- Tracing KPRX's Research & Development over 5 years: stood at $841617.0 in 2022, then jumped by 32.08% to $1.1 million in 2023, then sank by 33.47% to $739557.0 in 2024, then surged by 136.98% to $1.8 million in 2025, then gained by 21.18% to $2.1 million in 2026.
- The last three Research & Development figures came in at $2.1 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.08 Mn |
| Mar 31, 2026 | 2.12 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Sep 30, 2025 | 1.66 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 2.53 Mn |
| Dec 31, 2024 | 739,557.00 |
| Sep 30, 2024 | 868,198.00 |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 189,904.00 |
| Dec 31, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 1.39 Mn |
| Mar 31, 2023 | 438,283.00 |
| Dec 31, 2022 | 841,617.00 |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 567,227.00 |
| Mar 31, 2022 | 707,928.00 |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 1.63 Mn |